Examining quality of life with apremilast in white and nonwhite patients with psoriasis: Analysis of the ESTEEM, PSOR-011, and UNVEIL trials

Background: Patients (pts) with psoriasis often report impaired quality of life (QOL). Apremilast demonstrated improved QOL in pts with moderate to severe psoriasis in the phase 2b PSOR-011 and phase 3 ESTEEM 1 and 2 (EST) studies and in pts with moderate psoriasis in the phase 4 UNVEIL study. We compared QOL findings in white and nonwhite pts in the pooled EST population and in PSOR-011 (nonwhite only) and UNVEIL.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research